Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The test performed poorly in detecting cancers in two large studies.
- Simplified Text
-
Grail's multi-cancer blood test performed poorly in detecting cancers in two large studies.
- Confidence Score
- 1.000
- Claim Maker
- The author
- Context Type
- News Article
- Context Details
-
{ "source": "two large studies", "product": "multi-cancer blood test", "organization": "Grail" } - Subject Tags
- UUID
- 92345bce-2b44-47f3-9f28-d10f9e1785b3
- Vector Index
- ✗ No vector
- Created
- September 24, 2026 at 10:04 PM (2 weeks ago)
- Last Updated
- September 24, 2026 at 10:04 PM (2 weeks ago)
Original Sources for this Claim (0)
All source submissions that originally contained this claim.
No sources found
This claim is not associated with any source submissions.
Similar Claims (5)
Other claims identified as semantically similar to this one.
-
Simplified: Grail's multi-cancer blood test performed poorly in detecting cancers in two large studies.2 weeks ago
-
Simplified: The company Grail, which is seeking FDA approval for its multi-cancer blood test, was a top sponsor of the MAHA Summit in late 2026.2 weeks ago
-
Simplified: The company Grail, which is seeking FDA approval for a multi-cancer blood test, was a top sponsor of the MAHA Summit held in Washington in late Septem...2 weeks ago
-
Simplified: A new treatment for high-risk pancreatic cancer patients with removed tumors involves a vaccine using mRNA technology.3 weeks ago
-
Simplified: The drug daraxonrasib, recently approved by the FDA, doubled life expectancy to over 13 months for certain metastatic pancreatic cancer patients in a...3 weeks ago